Andrew D Cook Selected Research

Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)

11/2020	Granulocyte-Macrophage Colony Stimulating Factor As an Indirect Mediator of Nociceptor Activation and Pain.
1/2020	IL-23 in arthritic and inflammatory pain development in mice.
1/2019	GM-CSF- and IRF4-Dependent Signaling Can Regulate Myeloid Cell Numbers and the Macrophage Phenotype during Inflammation.
10/2018	CSF-1 in Inflammatory and Arthritic Pain Development.
2/2018	Investigational therapies targeting the granulocyte macrophage colony-stimulating factor receptor-α in rheumatoid arthritis: focus on mavrilimumab.
1/2018	CCL17 blockade as a therapy for osteoarthritis pain and disease.
1/2018	Glucocorticoids promote apoptosis of proinflammatory monocytes by inhibiting ERK activity.
1/2018	Cytokine-Induced Acute Inflammatory Monoarticular Arthritis.
1/2018	TNF and granulocyte macrophage-colony stimulating factor interdependence mediates inflammation via CCL17.
12/2016	Anti-colony-stimulating factor therapies for inflammatory and autoimmune diseases.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Andrew D Cook Research Topics

Disease

15	Arthritis (Polyarthritis) 01/2020 - 01/2010
15	Inflammation (Inflammations) 01/2019 - 04/2004
13	Rheumatoid Arthritis 02/2018 - 03/2002
12	Pain (Aches) 11/2020 - 09/2012
8	Peritonitis 01/2019 - 11/2003
4	Autoimmune Diseases (Autoimmune Disease) 12/2016 - 10/2004
4	Experimental Arthritis 01/2013 - 03/2002
3	Osteoarthritis 01/2018 - 01/2004
3	Neoplasms (Cancer) 12/2016 - 10/2011
3	Disease Progression 01/2016 - 01/2005
3	Pneumonia (Pneumonitis) 07/2015 - 04/2004
2	Necrosis 01/2020 - 02/2018
2	Infections 12/2016 - 04/2004
2	Wounds and Injuries (Trauma) 05/2014 - 01/2010
1	Chronic Pain 11/2020
1	Osteophyte 01/2018
1	Chronic Periodontitis 01/2017
1	Periodontitis 06/2015
1	Neoplasm Metastasis (Metastasis) 08/2014
1	Breast Neoplasms (Breast Cancer) 08/2014
1	Atrophy 05/2014
1	Traumatic Brain Injuries (Traumatic Brain Injury) 05/2014
1	Neurodegenerative Diseases (Neurodegenerative Disease) 05/2014
1	Gliosis 05/2014
1	Synovitis 09/2012
1	Anorexia 10/2011
1	Cachexia 10/2011
1	Immune System Diseases (Immune Disorders) 12/2004
1	Lung Diseases (Lung Disease) 04/2004

Drug/Important Bio-Agent (IBA)

21	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 11/2020 - 04/2004
13	CytokinesIBA 11/2020 - 10/2004
7	Macrophage Colony-Stimulating FactorIBA 10/2018 - 04/2007
5	methylated bovine serum albumin (MBSA)IBA 01/2020 - 11/2003
5	ZymosanIBA 01/2020 - 01/2017
5	Monoclonal AntibodiesIBA 12/2016 - 08/2011
5	Urokinase-Type Plasminogen Activator (Urokinase)FDA Link 06/2015 - 03/2002
4	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 01/2017 - 08/2014
4	AntigensIBA 12/2016 - 01/2010
3	Antigen-Antibody Complex (Immune Complex)IBA 01/2016 - 01/2010
2	Indomethacin (Indometacin)FDA LinkGeneric 01/2020 - 02/2013
2	Prostaglandin-Endoperoxide Synthases (Cyclooxygenase)IBA 01/2020 - 02/2013
2	LigandsIBA 01/2020 - 01/2018
2	Tumor Necrosis Factor InhibitorsIBA 01/2019 - 02/2018
2	Collagenases (Collagenase)FDA Link 01/2018 - 09/2012
2	Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)IBA 01/2018 - 01/2017
2	Granulocyte Colony-Stimulating Factor Receptors (G-CSF Receptor)IBA 01/2017 - 08/2014
2	Toll-Like Receptors (Toll-Like Receptor)IBA 01/2016 - 01/2011
2	ChemokinesIBA 01/2016 - 01/2016
2	Fibrinolysin FDA Link 06/2015 - 01/2010
2	Plasminogen Activators (Plasminogen Activator)IBA 06/2015 - 03/2002
2	Neutralizing AntibodiesIBA 08/2014 - 04/2004
2	AntibodiesIBA 08/2014 - 01/2004
2	Matrix Metalloproteinases (MMPs)IBA 09/2012 - 04/2004
2	CollagenIBA 01/2011 - 01/2004
2	LipopolysaccharidesIBA 01/2011 - 04/2004
2	Collagen Type II (Type II Collagen)IBA 01/2010 - 01/2004
2	FibrinIBA 04/2006 - 03/2002
2	Tissue Plasminogen Activator (Alteplase)FDA Link 04/2006 - 03/2002
1	Nerve Growth Factor (NGF)IBA 11/2020
1	Conditioned Culture MediaIBA 11/2020
1	Interleukin-23 (Interleukin 23)IBA 01/2020
1	EicosanoidsIBA 01/2020
1	Methotrexate (Mexate)FDA LinkGeneric 01/2019
1	GlucocorticoidsIBA 01/2019
1	Interleukin-1 (Interleukin 1)IBA 01/2019
1	Biomarkers (Surrogate Marker)IBA 02/2018
1	mavrilimumabIBA 02/2018
1	CCR4 ReceptorsIBA 01/2018
1	InflammasomesIBA 01/2017
1	Cell Surface ReceptorsIBA 01/2017
1	Colony-Stimulating Factors (Colony Stimulating Factor)IBA 12/2016
1	Interleukin-3 (Interleukin 3)IBA 12/2016
1	Interleukin-6 (Interleukin 6)IBA 12/2016
1	IntegrinsIBA 01/2016
1	Fc Receptors (Fc Receptor)IBA 01/2016
1	AutoantigensIBA 01/2016
1	AutoantibodiesIBA 01/2016
1	Complement System Proteins (Complement)IBA 01/2016
1	PlasminogenIBA 06/2015
1	Nicotinic Receptors (Nicotinic Acetylcholine Receptor)IBA 03/2015
1	Cholinergic Agents (Cholinergics)IBA 03/2015
1	Nicotinic AgonistsIBA 03/2015
1	Muscarinic AgonistsIBA 03/2015
1	Neuroprotective AgentsIBA 05/2014
1	salicylhydroxamic acid (SHAM)IBA 05/2014
1	Freund's AdjuvantIBA 02/2013
1	Cyclooxygenase InhibitorsIBA 02/2013
1	Phosphoric Monoester Hydrolases (Phosphatases)IBA 01/2013
1	Messenger RNA (mRNA)IBA 01/2013
1	Macrophage Colony-Stimulating Factor Receptor (Receptor, Macrophage Colony Stimulating Factor)IBA 04/2012
1	Proteoglycans (Proteoglycan)IBA 01/2010
1	Histocompatibility Antigens Class IIIBA 01/2010
1	Transcription Factors (Transcription Factor)IBA 04/2007
1	estropipate (Ogen)FDA LinkGeneric 04/2006
1	Pharmaceutical PreparationsIBA 12/2004
1	Irritants (Vesicants)IBA 10/2004
1	EndotoxinsIBA 04/2004
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 04/2004

Therapy/Procedure

7	Therapeutics 01/2019 - 04/2007
1	Investigational Therapies (Experimental Therapy) 02/2018